Table 1.

Baseline Characteristics of Patients in Clinical Trial Phases 2 and 3

	Phase 2	Phase 3	Phase 3
	CAMMS 223*	CARE-MS I	CARE-MS II*
	N = 333	N = 581	N = 637
Mean age in years (SD)	32.3 (8.5)	33.0 (8.2)	35.1 (8.6)
Gender (% Female)	64.3	64.7	66.9
Mean EDSS score (SD)	2.0 (0.7)	2.0 (0.8)	2.7 (1.2)
Median disease duration in years (range)	1.3 (0.1-6.3)	1.7 (0.1-6.0)	3.8 (0.2-16.9)
Mean no. relapses in past 2 years (range)	2.3 (1-7)	2.4 (1-7)	2.7 (1-9)

CAMMS = Campath in Multiple Sclerosis; EDDS = Expanded Disability Status Scale; MS = Multiple Sclerosis

*Only including patients on the 12 mg/kg alemtuzumab arm